Scholar Rock Holding (SRRK) Cash from Investing Activities (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Cash from Investing Activities of -$5.3 million for Q1 2026, down 115.44% year-over-year from $34.6 million in Q1 2025, and down 113.69% quarter-over-quarter from $39.0 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$5.3 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 115.44% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at $178.8 million (up 338.76% YoY), while the FY2025 annual figure was $218.7 million, up 387.53% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$5.3 million, down from $39.0 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $90.0 million in Q1 2023, with the low at -$195.4 million in Q4 2024.
- The 5-year median for Cash from Investing Activities is $33.4 million (2024), against an average of $396411.8.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 32733.77% in 2023, then jumped 516.71% in 2024.
- Scholar Rock Holding's Cash from Investing Activities stood at $77000.0 in 2022, then plunged by 32733.77% to -$25.1 million in 2023, then sank by 677.5% to -$195.4 million in 2024, then surged by 119.95% to $39.0 million in 2025, then sank by 113.69% to -$5.3 million in 2026.
- Business Quant data shows SRRK's Cash from Investing Activities at -$5.3 million in Q1 2026, $39.0 million in Q4 2025, and $59.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Scholar Rock Holding | 7.19 Bn | 7.19 Bn | - | -5.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.50 Mn |
| Mar 31, 2026 | -5.34 Mn |
| Dec 31, 2025 | 38.97 Mn |
| Sep 30, 2025 | 59.70 Mn |
| Jun 30, 2025 | 85.47 Mn |
| Mar 31, 2025 | 34.55 Mn |
| Dec 31, 2024 | -195.37 Mn |
| Sep 30, 2024 | 35.31 Mn |
| Jun 30, 2024 | 50.62 Mn |
| Mar 31, 2024 | 33.38 Mn |
| Dec 31, 2023 | -25.13 Mn |
| Sep 30, 2023 | -8.47 Mn |
| Jun 30, 2023 | -15.24 Mn |
| Mar 31, 2023 | 89.98 Mn |
| Dec 31, 2022 | 77,000.00 |
| Sep 30, 2022 | -145.72 Mn |
| Jun 30, 2022 | 44.52 Mn |
| Mar 31, 2022 | -70.58 Mn |
| Dec 31, 2021 | 29.46 Mn |
| Sep 30, 2021 | 3.28 Mn |